Dr. Weight Loss of Atlanta - Chamblee
Dr. Weight Loss of Atlanta - Chamblee · 5070 Peachtree Boulevard · Chamblee, GA 30341
5.0· 21 Google reviews
Listing updated October 2, 2026
Quick facts
- Address
- 5070 Peachtree Boulevard, Chamblee, GA 30341
- Phone
- (770) 330-4214
- Website
- drweightlossofatlanta.com
- Telehealth
- Not listed
- FDA-approved GLP-1 medications listed
- None listed on its website
- Accepting new patients (per website)
- Yes
- Accepts insurance (per website)
- Yes
- Google rating
- ★5.0 from 21 reviews
- Patient sentiment
- 100% positive, 0% negative (21 reviews analyzed)
- Most praised
- Weight-loss results (7 reviews)
- Most common complaint
- None recurring
- Retatrutide
- Not yet available anywhere — investigational, not FDA-approved
- Listing last updated
- October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
Dr. Weight Loss of Atlanta - Chamblee is a weight-loss practice in Chamblee, Georgia. Its website introduces founder Dr. Alex Roig, who it says earned a doctorate of chiropractic and a bachelor's degree in nutrition and previously worked as a personal trainer, and describes a team focused on weight loss, wellness and holistic health. The site covers semaglutide as a weight-loss option. This location has a 5.0-star Google rating across 21 reviews since 2020, only 1 of them in the past year, and results are the theme reviewers mention most, in seven reviews.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2025-10-08. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 21 Google reviews. Of the 21 reviews we analyzed, 21 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Weight-loss results7 reviews
- Knowledgeable, professional providers4 reviews
- Feeling listened to2 reviews
Common complaints
No negative reviews among those we analyzed.
Most recent Google reviews
Refugio M.★★★★★2025-10-08Dr.Alex was great, answered all of my concerns and explained through each option I had. Definitely recommend and I am definitely going back!
Nate S.★★★★★2025-08-11Very helpful initial consultation.
Caitlyn S.★★★★★2025-07-14He listened and was very informative
Yolanda R.★★★★★2025-06-10Great consultation. Dr. Alex provided a thorough explanation of a weight loss journey and provided recommendations on what was best for me. He also makes himself available to answer your questions.
Brandie D.★★★★★2025-02-28I had a very pleasant experience with Dr. Alex. He was incredibly informative about my weight-loss options and had knowledge about keeping the weight off!! I’ll certainly recommend going!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs